Evidence map›Paper›PMID 34207482›Full record

ReviewBiology2021

Autophagy a Close Relative of AML Biology.

Carine Joffre, Charlotte Ducau, Laura Poillet-Perez, Charly Courdy, Véronique Mansat-De Mas

Abstract readReview
In one paragraph

Review in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Frontiers in oncology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. The dual role of autophagy in acute myeloid leukemia.Journal of hematology & oncology · 2022
    Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Carine JoffreCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Inserm, CNRS, 31037 Toulouse, France.ORCID 0000-0002-7551-356X
Charlotte DucauCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Inserm, CNRS, 31037 Toulouse, France.
Laura Poillet-PerezCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Inserm, CNRS, 31037 Toulouse, France.
Charly CourdyCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Inserm, CNRS, 31037 Toulouse, France.
Véronique Mansat-De MasCentre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Inserm, CNRS, 31037 Toulouse, France.ORCID 0000-0003-1878-9129

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autophagy, which literally means "eat yourself", is more than just a lysosomal degradation pathway. It is a well-known regulator of cellular metabolism and a mechanism implicated in tumor initiation/progression and therapeutic resistance in many cancers. However, whether autophagy acts as a tumor suppressor or promoter is still a matter of debate. In acute myeloid leukemia (AML), it is now proven that autophagy supports cell proliferation in vitro and leukemic progression in vivo. Mitophagy, the specific degradation of mitochondria through autophagy, was recently shown to be required for leukemic stem cell functions and survival, highlighting the prominent role of this selective autophagy in leukemia initiation and progression. Moreover, autophagy in AML sustains fatty acid oxidation through lipophagy to support mitochondrial oxidative phosphorylation (OxPHOS), a hallmark of chemotherapy-resistant cells. Nevertheless, in the context of therapy, in AML, as well as in other cancers, autophagy could be either cytoprotective or cytotoxic, depending on the drugs used. This review summarizes the recent findings that mechanistically show how autophagy favors leukemic transformation of normal hematopoietic stem cells, as well as AML progression and also recapitulates its ambivalent role in resistance to chemotherapies and targeted therapies.

Indexed as

AMLautophagyhematopoiesismitophagytherapy

Identifiers

PMID34207482
PMCPMC8235674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.